274 related articles for article (PubMed ID: 34572083)
21. PARP Inhibitors for Cancer Therapy.
Lin KY; Kraus WL
Cell; 2017 Apr; 169(2):183. PubMed ID: 28388401
[TBL] [Abstract][Full Text] [Related]
22. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
23. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
24. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
25. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
[TBL] [Abstract][Full Text] [Related]
26. Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
Perez JM; Twigg CAI; Guan W; Thomas SN
J Am Soc Mass Spectrom; 2022 Feb; 33(2):242-250. PubMed ID: 34958553
[TBL] [Abstract][Full Text] [Related]
27. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
Schettini F; Giudici F; Bernocchi O; Sirico M; Corona SP; Giuliano M; Locci M; Paris I; Scambia G; De Placido S; Rescigno P; Prat A; Curigliano G; Generali D
Eur J Cancer; 2021 May; 149():134-152. PubMed ID: 33862496
[TBL] [Abstract][Full Text] [Related]
28. Rucaparib Approved for Ovarian Cancer.
Cancer Discov; 2017 Feb; 7(2):120-121. PubMed ID: 28057616
[TBL] [Abstract][Full Text] [Related]
29. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Swisher EM; Kristeleit RS; Oza AM; Tinker AV; Ray-Coquard I; Oaknin A; Coleman RL; Burris HA; Aghajanian C; O'Malley DM; Leary A; Welch S; Provencher D; Shapiro GI; Chen LM; Shapira-Frommer R; Kaufmann SH; Goble S; Maloney L; Kwan T; Lin KK; McNeish IA
Gynecol Oncol; 2021 Dec; 163(3):490-497. PubMed ID: 34602290
[TBL] [Abstract][Full Text] [Related]
30. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
31. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2.
Tsang ES; Dhawan MS; Pacaud R; Thomas S; Grabowsky J; Wilch L; Karipineni S; Kelley RK; Ko AH; Collisson E; Chapman JS; Ueda S; Bergsland EK; Munster P
JCO Precis Oncol; 2024 Jun; 8():e2300494. PubMed ID: 38865673
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic Application of PARP Inhibitors in Neuro-Oncology.
Ning J; Wakimoto H
Trends Cancer; 2020 Feb; 6(2):147-159. PubMed ID: 32061304
[TBL] [Abstract][Full Text] [Related]
33. How safe is rucaparib in ovarian cancer?
Cosgrove CM; O'Malley DM
Expert Opin Drug Saf; 2018 Dec; 17(12):1249-1255. PubMed ID: 30449210
[No Abstract] [Full Text] [Related]
34. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
Chopra N; Tovey H; Pearson A; Cutts R; Toms C; Proszek P; Hubank M; Dowsett M; Dodson A; Daley F; Kriplani D; Gevensleben H; Davies HR; Degasperi A; Roylance R; Chan S; Tutt A; Skene A; Evans A; Bliss JM; Nik-Zainal S; Turner NC
Nat Commun; 2020 May; 11(1):2662. PubMed ID: 32471999
[TBL] [Abstract][Full Text] [Related]
35. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
Herzog TJ; Vergote I; Gomella LG; Milenkova T; French T; Tonikian R; Poehlein C; Hussain M
Eur J Cancer; 2023 Jan; 179():136-146. PubMed ID: 36563604
[TBL] [Abstract][Full Text] [Related]
36. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
37.
Ramos CRN; Oliveira RJS; Rosa MN; Pereira AS; de Abreu RBV; van Helvoort Lengert A; Reis RM; Silva VAO; Palmero EI; Melendez ME
Curr Cancer Drug Targets; 2023; 23(11):900-909. PubMed ID: 37076963
[TBL] [Abstract][Full Text] [Related]
38. Update on PARP Inhibitors in Breast Cancer.
Zimmer AS; Gillard M; Lipkowitz S; Lee JM
Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
[TBL] [Abstract][Full Text] [Related]
39. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Kurnit KC; Coleman RL; Westin SN
Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
[TBL] [Abstract][Full Text] [Related]
40. Rucaparib: First Global Approval.
Syed YY
Drugs; 2017 Apr; 77(5):585-592. PubMed ID: 28247266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]